These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22643315)

  • 41. Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo.
    Zeisig R; Rückerl D; Fichtner I
    Anticancer Drugs; 2004 Aug; 15(7):707-14. PubMed ID: 15269602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel tubulin inhibitor STK899704 induces tumor regression in DMBA/TPA-induced skin carcinogenesis model.
    Hwang J; Soung NK; Han HJ; Lee Y; Choi TW; Mun J; Cha-Molstad H; Lee KH; Kim HJ; Lee HG; Hong JT; Ahn JS; Kwon YT; Kim BY
    Exp Dermatol; 2018 Mar; 27(3):285-288. PubMed ID: 29392819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Self-assembled rosette nanotubes for incorporating hydrophobic drugs in physiological environments.
    Song S; Chen Y; Yan Z; Fenniri H; Webster TJ
    Int J Nanomedicine; 2011 Jan; 6():101-7. PubMed ID: 21289987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Further findings on dermal changes in experimental skin carcinogenesis].
    PRODI G; MALTONI C
    Tumori; 1957; 43(5):466-76. PubMed ID: 13519548
    [No Abstract]   [Full Text] [Related]  

  • 45. Liposomal paclitaxel formulations.
    Koudelka S; Turánek J
    J Control Release; 2012 Nov; 163(3):322-34. PubMed ID: 22989535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
    Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
    Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality control of liposomal lipids with special emphasis on peroxidation of phospholipids and cholesterol.
    Lang JK; Vigo-Pelfrey C
    Chem Phys Lipids; 1993 Sep; 64(1-3):19-29. PubMed ID: 8242833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phlebotomy consent: ethical concerns.
    Rameshkumar K; Rao C
    Indian J Med Ethics; 2015; 12(2):122. PubMed ID: 25920975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tamoxifen citrate loaded ethosomes for transdermal drug delivery system: preparation and characterization.
    Sarwa KK; Suresh PK; Debnath M; Ahmad MZ
    Curr Drug Deliv; 2013 Aug; 10(4):466-76. PubMed ID: 23656399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex.
    Lin YL; Chen CH; Wu HY; Tsai NM; Jian TY; Chang YC; Lin CH; Wu CH; Hsu FT; Leung TK; Liao KW
    J Nanobiotechnology; 2016 Feb; 14():11. PubMed ID: 26892504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
    Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
    Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity.
    How CW; Rasedee A; Manickam S; Rosli R
    Colloids Surf B Biointerfaces; 2013 Dec; 112():393-9. PubMed ID: 24036474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
    Xu X; Wang L; Xu HQ; Huang XE; Qian YD; Xiang J
    Asian Pac J Cancer Prev; 2013; 14(4):2591-4. PubMed ID: 23725180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
    Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
    Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs.
    Oussoren C; Eling WM; Crommelin DJ; Storm G; Zuidema J
    Biochim Biophys Acta; 1998 Feb; 1369(1):159-72. PubMed ID: 9528684
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption.
    Abdullah Shamim M; Yeung S; Shahid A; Chen M; Wang J; Desai P; Parsa C; Orlando R; Meyskens FL; Kelly KM; Andresen BT; Huang Y
    Int J Pharm; 2022 Jan; 611():121302. PubMed ID: 34793935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic dissection of clonal lineage relationships with hydroxytamoxifen liposomes.
    Ransom RC; Foster DS; Salhotra A; Jones RE; Marshall CD; Leavitt T; Murphy MP; Moore AL; Blackshear CP; Brett EA; Wan DC; Longaker MT
    Nat Commun; 2018 Jul; 9(1):2971. PubMed ID: 30061668
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.